⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 6, 2019Science Translational MedicineOpen Access

Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus

Rita G. Kansal Noah Richardson Indira Neeli Saleem Khawaja Damian Chamberlain Marium Ghani Qurat-ul-ain Ghani Louisa Balázs Šárka Beranová-Giorgianni Francesco Giorgianni James N. Kochenderfer Tony N. Marion Lorraine M. Albritton Marko Radic

View Full Paper

Ask AI

Bookmark

Share

Abstract

CD19-targeted CAR T cells show sustained CD19 + B cell depletion and profound therapeutic benefit in ameliorating disease in mouse models of lupus.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kansal et al. (2019) studied this question.

synapsesocial.com/papers/698e2a1ab0728b1abf3b5750 https://doi.org/10.1126/scitranslmed.aav1648

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Systemic Lupus ErythematosusReview · 2008 · 1,635 citations
2B Cell Depletion with Anti-CD79 mAbs Ameliorates Autoimmune Disease in MRL/ <i>lpr</i> MiceOriginal Research · 2008 · 57 citations
3MEDI‐551 Treatment Effectively Depletes B Cells and Reduces Serum Titers of Autoantibodies in Mice Transgenic for <i>Sle1</i> and Human CD19Original Research · 2015 · 29 citations
4Current and future therapies for SLE: obstacles and recommendations for the development of novel treatmentsHuman Clinical Trial · 2017 · 104 citations
5Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeksRCT · 2006 · 1,638 citations

B-Cell Depletion — A Frontier in Monoclonal Antibodies for Multiple Sclerosis2016
Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial2009
Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis2018
The kinase inhibitor dabrafenib halts progression of cerebral cavernous malformations in a BRAF-independent mannerScience Translational Medicine · 2026
Targeting ZIP12-mediated Zn 2+ signaling as a treatment for pulmonary hypertensionScience Translational Medicine · 2026

More from Science Translational Medicine